 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...198199200201202203204205206207208...235236» |
- | Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
Enrollment closed, Enrollment change, Metastases: PREVIUM: Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab (clinicaltrials.gov) - Jul 13, 2016
P2, N=15, Active, not recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Recruiting --> Active, not recruiting | N=53 --> 15
- ||| namilumab (IZN-101) / Amgen, Izana Biosci, Roivant
Combination therapy: NEXUS: Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Jul 11, 2016
P2, N=108, Active, not recruiting, Sponsor: Takeda
Recruiting --> Active, not recruiting | N=53 --> 15 Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Nov 2016
- | Aphexda (motixafortide) / BioLineRx, Ayrmid
New P2 trial, Metastases: COMBAT: Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (clinicaltrials.gov) - Jul 11, 2016
P2, N=30, Not yet recruiting, Sponsor: BioLineRx, Ltd.
- | New P2 trial, Metastases: PRODIGE 37-FIRGEMAX: FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine (clinicaltrials.gov) - Jul 11, 2016
P2, N=124, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, LEAC-102 / Taiwan Bio
New P1/2 trial, Combination therapy, Metastases: LEAC-102 for Advanced Colorectal Cancer (clinicaltrials.gov) - Jul 11, 2016
P1/2, N=30, Not yet recruiting, Sponsor: Taiwan Leader Biotech Corp.
- | thioguanine / Generic mfg., azacitidine / Generic mfg.
New P2 trial: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Jul 11, 2016
P=N/A, N=116, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- |||| vanucizumab (RG7221) / Roche, Avastin (bevacizumab) / Roche
Enrollment open, Metastases: McCAVE: A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 5, 2016
P2, N=198, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Nov 2016 Active, not recruiting --> Recruiting
- |||| Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date, Metastases: STEAM: Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 5, 2016
P2, N=280, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Mar 2016
- buparlisib (AN2025) / Adlai Nortye
Trial completion, Enrollment change, Trial primary completion date, Metastases: BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer (clinicaltrials.gov) - Jul 5, 2016
P1, N=17, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Mar 2016 Recruiting --> Completed | N=60 --> 17 | Trial primary completion date: Jul 2016 --> May 2015
- |||| Erbitux (cetuximab) / Eli Lilly
Trial completion, Metastases: FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum (clinicaltrials.gov) - Jul 4, 2016
P2, N=238, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Completed | N=60 --> 17 | Trial primary completion date: Jul 2016 --> May 2015 Active, not recruiting --> Completed
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Trial completion: Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy (clinicaltrials.gov) - Jul 4, 2016
P=N/A, N=308, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion, Surgery: SWOG-C80002: Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer (clinicaltrials.gov) - Jul 4, 2016
P2, N=320, Completed, Sponsor: Alliance for Clinical Trials in Oncology
No longer recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion, Metastases: Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer (clinicaltrials.gov) - Jul 4, 2016
P2, N=44, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia (clinicaltrials.gov) - Jul 3, 2016
P2, N=134, Completed, Sponsor: Alliance for Clinical Trials in Oncology
No longer recruiting --> Completed Active, not recruiting --> Completed
- HyperAcute Pancreas (algenpantucel-L) / Lumos Pharma
Enrollment change, Trial termination: Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Jul 1, 2016
P2, N=10, Terminated, Sponsor: NewLink Genetics Corporation
Active, not recruiting --> Completed N=48 --> 10 | Active, not recruiting --> Terminated
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2/3 trial, Monotherapy: A Efficacy and Tolerability Study of TEGAFOX Sequential S-1 in the Treatment of Adjuvant Chemotherapy for Gastric Cancer (clinicaltrials.gov) - Jun 29, 2016
P2/3, N=300, Recruiting, Sponsor: LanZhou University
- |||||| napabucasin (BBI608) / Sumitomo Pharma
Enrollment open, Combination therapy, Metastases: CanStem303C trial: A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 29, 2016
P3, N=1250, Recruiting, Sponsor: Boston Biomedical, Inc
N=48 --> 10 | Active, not recruiting --> Terminated Not yet recruiting --> Recruiting
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open, Trial initiation date, Metastases: FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (clinicaltrials.gov) - Jun 29, 2016
P2, N=60, Recruiting, Sponsor: howard safran
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> Jun 2016
- Stivarga (regorafenib) / Bayer
Trial primary completion date, Metastases: FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer (clinicaltrials.gov) - Jun 28, 2016
P2, N=36, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> Jun 2016 Trial primary completion date: Jul 2016 --> Jul 2017
- || napabucasin (BBI608) / Sumitomo Pharma
Enrollment change, Combination therapy, Metastases: A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Jun 28, 2016
P1, N=509, Recruiting, Sponsor: Boston Biomedical, Inc
Trial primary completion date: Jul 2016 --> Jul 2017 N=168 --> 509
- |||||| BI 695502 (bevacizumab biosimilar) / Boehringer Ingelheim
Enrollment open, Metastases: INVICTAN (clinicaltrials.gov) - Jun 28, 2016
P3, N=120, Recruiting, Sponsor: Boehringer Ingelheim
N=168 --> 509 Not yet recruiting --> Recruiting
- Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Phase classification, PD(L)-1 Biomarker, Surgery, Metastases: Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Jun 28, 2016
P1b/2, N=68, Recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Phase classification: P1/2 --> P1b/2
- |||||| Enrollment open: Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer (clinicaltrials.gov) - Jun 24, 2016
P3, N=230, Recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
Not yet recruiting --> Recruiting | Phase classification: P1/2 --> P1b/2 Not yet recruiting --> Recruiting
- || leucovorin calcium / Generic mfg.
New P3 trial: Folinic Acid: Supplementation and Therapy (clinicaltrials.gov) - Jun 22, 2016
P3, N=69, Completed, Sponsor: Hospital de Clinicas de Porto Alegre
- sunitinib / Generic mfg.
Trial termination, Metastases: Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer (clinicaltrials.gov) - Jun 21, 2016
P1, N=23, Terminated, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; PI left institute
- |||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Combination therapy: LUD2015-005: Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer (clinicaltrials.gov) - Jun 18, 2016
P1/2, N=75, Recruiting, Sponsor: Ludwig Institute for Cancer Research
Active, not recruiting --> Terminated; PI left institute Not yet recruiting --> Recruiting
- Removab (catumaxomab) / NeoPharm, Trion Pharma
Trial primary completion date: Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas (clinicaltrials.gov) - Jun 16, 2016
P2, N=42, Active, not recruiting, Sponsor: AIO-Studien-gGmbH
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2016 --> Jul 2016
- leucovorin calcium / Generic mfg.
Enrollment open, Phase classification: EFFET: Folinic Acid in Children With Autism Spectrum Disorders (clinicaltrials.gov) - Jun 16, 2016
P2, N=40, Recruiting, Sponsor: Central Hospital, Nancy, France
Trial primary completion date: Mar 2016 --> Jul 2016 Not yet recruiting --> Recruiting | Phase classification: P4 --> P2
- || 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date: Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Jun 15, 2016
P2, N=120, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting | Phase classification: P4 --> P2 Trial primary completion date: Oct 2016 --> Oct 2017
- | otilimab (GSK3196165) / GSK
New P2a trial, Combination therapy: Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jun 15, 2016
P2a, N=40, Not yet recruiting, Sponsor: GlaxoSmithKline
- || AZD0156 / AstraZeneca
Trial primary completion date, Combination therapy, Monotherapy, PARP Biomarker, Metastases: AToM: Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (clinicaltrials.gov) - Jun 13, 2016
P1, N=225, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: Oct 2016 --> Oct 2017 Trial primary completion date: Sep 2018 --> Mar 2019
- |||| Erbitux (cetuximab) / Eli Lilly
Trial completion, Metastases: Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jun 11, 2016
P2, N=245, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Sep 2018 --> Mar 2019 Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., metformin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jun 10, 2016
P2, N=43, Recruiting, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Dec 2016
- Cyramza (ramucirumab) / Eli Lilly
Phase classification, Metastases: A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer (clinicaltrials.gov) - Jun 10, 2016
P1b, N=9, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Jun 2016 --> Dec 2016 Phase classification: P1 --> P1b
- | Cyramza (ramucirumab) / Eli Lilly
Enrollment open, Combination therapy: FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) (clinicaltrials.gov) - Jun 9, 2016
P2/3, N=908, Recruiting, Sponsor: Krankenhaus Nordwest
Phase classification: P1 --> P1b Not yet recruiting --> Recruiting
- Trial primary completion date: A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients (clinicaltrials.gov) - Jun 5, 2016
P2, N=31, Recruiting, Sponsor: University of Michigan Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2016 --> Feb 2017
- ||| Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial completion, Trial primary completion date, Combination therapy, Metastases: Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) (clinicaltrials.gov) - Jun 5, 2016
P1, N=180, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2016 --> Feb 2017 Active, not recruiting --> Completed | Trial primary completion date: Aug 2025 --> May 2016
- || ipatasertib (RG7440) / Roche
Trial primary completion date, Combination therapy, Metastases: Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 5, 2016
P1, N=118, Active, not recruiting, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Aug 2025 --> May 2016 Trial primary completion date: Nov 2015 --> Feb 2017
- dexamethasone / Generic mfg., floxuridine / Generic mfg.
Trial primary completion date, Combination therapy: Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver (clinicaltrials.gov) - Jun 5, 2016
P2, N=64, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Nov 2015 --> Feb 2017 Trial primary completion date: May 2016 --> May 2017
- futuximab/modotuximab (S95026) / Servier
Phase classification, Combination therapy, Metastases: Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Jun 5, 2016
P1b/2a, N=50, Recruiting, Sponsor: Symphogen A/S
Trial primary completion date: May 2016 --> May 2017 Phase classification: P1/2 --> P1b/2a
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open: NORMAL-R: Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum (clinicaltrials.gov) - Jun 5, 2016
P0, N=20, Recruiting, Sponsor: Washington University School of Medicine
Phase classification: P1/2 --> P1b/2a Not yet recruiting --> Recruiting
- ||| vanucizumab (RG7221) / Roche, Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: McCAVE: A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 2, 2016
P2, N=187, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | HyperAcute Pancreas (algenpantucel-L) / Lumos Pharma
Enrollment closed: Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Jun 1, 2016
P2, N=48, Active, not recruiting, Sponsor: NewLink Genetics Corporation
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date: FFCD 1201 DEBIRI: Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study (clinicaltrials.gov) - May 31, 2016
P2, N=58, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2016 --> Jan 2017
- Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: PRODIGE 9: Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 31, 2016
P3, N=492, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Trial primary completion date: Jul 2016 --> Jan 2017 Trial primary completion date: Jul 2015 --> Dec 2015
- | Enrollment closed, Surgery: CALGB: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery (clinicaltrials.gov) - May 31, 2016
P3, N=2500, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Jul 2015 --> Dec 2015 Recruiting --> Active, not recruiting
- |||| Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date, Metastases: PRODIGE-20: 1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 31, 2016
P2, N=102, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Sep 2014
- Erbitux (cetuximab) / Eli Lilly
Trial completion, Trial primary completion date: Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction (clinicaltrials.gov) - May 31, 2016
P2, N=65, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Sep 2014 Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Mar 2013
- Avastin (bevacizumab) / Roche
Trial completion, Enrollment change, Metastases: Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 31, 2016
P2, N=86, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Mar 2013 Recruiting --> Completed | N=108 --> 86
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion: Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery (clinicaltrials.gov) - May 31, 2016
P2, N=20, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Recruiting --> Completed | N=108 --> 86 Active, not recruiting --> Completed